JAVIER
PUENTE VÁZQUEZ
Profesor asociado de Ciencias de la Salud
Hospital del Mar
Barcelona, EspañaPublicaciones en colaboración con investigadores/as de Hospital del Mar (14)
2024
-
Phase II trial of afatinib in patients with advanced urothelial carcinoma with genetic alterations in ERBB1-3 (LUX-Bladder 1)
British Journal of Cancer, Vol. 130, Núm. 3, pp. 434-441
2023
-
Exploratory analyses of treatment subgroup interaction by PD-L1 status and according to PD-L1 expression in the JAVELIN Bladder 100 trial
Clinical and Translational Oncology
2020
2019
-
Plasma Androgen Receptor and Docetaxel for Metastatic Castration-resistant Prostate Cancer
European Urology, Vol. 75, Núm. 3, pp. 368-373
-
Prorepair-B: A prospective cohort study of the impact of germline DNA repair mutations on the outcomes of patients with metastatic castration-resistant prostate cancer
Journal of Clinical Oncology, Vol. 37, Núm. 6, pp. 490-503
-
The Challenge of Managing Bladder Cancer and Upper Tract Urothelial Carcinoma: A Review with Treatment Recommendations from the Spanish Oncology Genitourinary Group (SOGUG)
Targeted Oncology, Vol. 14, Núm. 1, pp. 15-32
2017
-
Maintenance therapy with vinflunine plus best supportive care versus best supportive care alone in patients with advanced urothelial carcinoma with a response after first-line chemotherapy (MAJA; SOGUG 2011/02): a multicentre, randomised, controlled, open-label, phase 2 trial
The Lancet Oncology, Vol. 18, Núm. 5, pp. 672-681
2016
2015
-
Recomendaciones para el diagnóstico radiológico y la valoración de la respuesta terapéutica en el cáncer de pulmón. Consenso nacional de la Sociedad Española de Radiología Médica y la Sociedad Española de Oncología Médica
Radiologia, Vol. 57, Núm. 1, pp. 66-78
-
Recommendations for radiological diagnosis and assessment of treatment response in lung cancer: a national consensus statement by the Spanish Society of Medical Radiology and the Spanish Society of Medical Oncology
Clinical and Translational Oncology, Vol. 17, Núm. 1, pp. 11-23
2014
-
Identification of tissue microRNAs predictive of sunitinib activity in patients with metastatic renal cell carcinoma
PLoS ONE, Vol. 9, Núm. 1
-
SEOM clinical guidelines for the treatment of renal cell carcinoma
Clinical and Translational Oncology, Vol. 16, Núm. 12, pp. 1043-1050
2013
-
Prospective study assessing hypoxia-related proteins as markers for the outcome of treatment with sunitinib in advanced clear-cell renal cell carcinoma
Annals of Oncology, Vol. 24, Núm. 9, pp. 2409-2414
2011
-
Single nucleotide polymorphism associations with response and toxic effects in patients with advanced renal-cell carcinoma treated with first-line sunitinib: A multicentre, observational, prospective study
The Lancet Oncology, Vol. 12, Núm. 12, pp. 1143-1150